Evidence map›Paper›PMID 32038746›Full record

ReviewThe Journal of clinical and aesthetic dermatology2019

ONYCHOMYCOSIS: A Review of New and Emerging Topical and Device-based Treatments.

Nisrine Kawa, Kachiu C Lee, R Rox Anderson, Lilit Garibyan

Open access · greenAbstract readReview
In one paragraph

Review in The Journal of clinical and aesthetic dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Nisrine KawaDrs. Kawa, Anderson, and Garibyan are with the Wellman Center for Photomedicine at Massachusetts General Hospital and the Department of Dermatology at Harvard Medical School in Boston, Massachusetts.
Kachiu C LeeDrs. Kawa, Anderson, and Garibyan are with the Wellman Center for Photomedicine at Massachusetts General Hospital and the Department of Dermatology at Harvard Medical School in Boston, Massachusetts.
R Rox AndersonDrs. Kawa, Anderson, and Garibyan are with the Wellman Center for Photomedicine at Massachusetts General Hospital and the Department of Dermatology at Harvard Medical School in Boston, Massachusetts.
Lilit GaribyanDrs. Kawa, Anderson, and Garibyan are with the Wellman Center for Photomedicine at Massachusetts General Hospital and the Department of Dermatology at Harvard Medical School in Boston, Massachusetts.
Brown University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Onychomycosis is a challenging nail condition to treat. The gold standard treatment relies on long-term systemic therapy, which carries risks of potential side effects and drug interactions. Topical alternatives exist; however, treatment outcomes remain disappointing. In this article, we review newer topical formulations that are approved by the United States Food and Drug Administration, as well as other topical drugs that are still undergoing clinical trials. Lasers and energy-based devices have also been used for the treatment of onychomycosis; however, standardized parameters and clear treatment endpoints have yet to be specified. Currently, device-based therapies are considered as options for improving the cosmetic appearance of nails. The use of lasers to improve the penetration of topical antifungal treatments as possible combination treatments is also reviewed.

Indexed as

Antifungalfunguslasernailonychomycosis

Identifiers

PMID32038746
PMCPMC6937150
OpenAlexW3010369850

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.